Emerging Opportunities for Serotypes of Botulinum Neurotoxins

Background: Two decades ago, botulinum neurotoxin (BoNT) type A was introduced to the commercial market. Subsequently, the toxin was approved by the FDA to address several neurological syndromes, involving muscle, nerve, and gland hyperactivity. These syndromes have typically been associated with ab...

Descripción completa

Detalles Bibliográficos
Autores principales: Peng Chen, Zhongxing, Morris, J. Glenn, Rodriguez, Ramon L., Shukla, Aparna Wagle, Tapia-Núñez, John, Okun, Michael S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2012
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3509704/
https://www.ncbi.nlm.nih.gov/pubmed/23202312
http://dx.doi.org/10.3390/toxins4111196

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3509704/
https://www.ncbi.nlm.nih.gov/pubmed/23202312
http://dx.doi.org/10.3390/toxins4111196

Ejemplares similares